Novartis will pay $72 a share in cash for the biotechnology company, representing a premium of 46% to Avidity’s closing price ...

(Oct 27): Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc in a deal valued at US$12 billion, making ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

Some companies are pitching a new model for employers to help their workers pay for medications, but without using insurance.

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

NEW YORK] Novartis agreed to buy biotechnology company Avidity Biosciences in a deal that values it at US$12 billion, ...

Alexandria Real Estate Equities, Inc. faces ongoing headwinds, with soft biotech demand, and declining occupancy. Learn more ...

The biotechnology giant’s board will front angry investors this week after losing more than a quarter of its market value ...

The Mass. Life Sciences Center is making 21 companies pay back tax breaks they received for failing to meet their hiring ...

Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the ...

GV- and Arch-backed Pelage Pharma is developing a first-of-its-kind topical stem-cell therapy that could redefine the $10B ...

Choosing the right career path after completing 12th grade in the science stream is crucial for securing a lucrative and ...